Preeclampsia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major preeclampsia markets reached a value of US$ 712.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 856.5 Million by 2034, exhibiting a growth rate (CAGR) of 1.69% during 2024-2034.
The preeclampsia market has been comprehensively analyzed in IMARC's new report titled "Preeclampsia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Preeclampsia is a pregnancy-related complication that typically affects after the 20th week of pregnancy and is characterized by high blood pressure and damage to organs, such as the liver and kidneys. In some cases, this condition can be life-threatening for both the mother and the baby, and it may lead to preterm delivery or other health issues. The common symptoms of the ailment include high blood pressure, proteinuria, decreased platelet levels in the blood, increased liver enzymes, severe headaches, changes in vision, shortness of breath, pain in the upper belly, nausea, vomiting, sudden appearance of edema, etc. The diagnosis of preeclampsia is based on a review of the patient's symptoms, medical history, and a physical exam. The healthcare provider may also perform other frequently used diagnostic investigations, such as fetal ultrasound, urine analysis, blood workup, non-stress test, or biophysical profile.
The rising cases of placental-related diseases on account of reduced blood supply to the placenta, resulting in a hypoxic environment, are primarily driving the preeclampsia market. In addition to this, the increasing incidences of several associated risk factors, including genetic aspects, blood vessel problems, multiple pregnancies, advancing age, autoimmune disorders, obesity, use of in vitro fertilization, etc., are also bolstering the market growth. Furthermore, the widespread adoption of intravenous antihypertensive drugs to lower blood pressure in patients with quicker onset of action than oral therapy is acting as another significant growth-inducing factor. In line with this, the escalating demand for steroid injections that help the baby's lungs mature more quickly before being born, reduce fetal abnormalities, and improve outcomes in preterm birth, is also creating a positive outlook for the market. Moreover, various stakeholders are making significant investments in research activities to develop novel diagnostic tools for early detection of the condition and encourage treatment monitoring among the population. This, in turn, is also augmenting the market growth. Additionally, the emerging popularity of angiogenic biomarkers, which accelerate diagnosis and minimize adverse maternal outcomes to help enable risk stratification, along with appropriate resource redistribution, is expected to drive the preeclampsia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the preeclampsia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for preeclampsia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the preeclampsia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the preeclampsia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the preeclampsia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current preeclampsia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Drugs Company Name
Antithrombin gamma Kyowa Kirin
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the preeclampsia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the preeclampsia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the preeclampsia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of preeclampsia across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of preeclampsia by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of preeclampsia by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with preeclampsia across the seven major markets?
What is the size of the preeclampsia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of preeclampsia?
What will be the growth rate of patients across the seven major markets?
Preeclampsia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for preeclampsia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the preeclampsia market?
What are the key regulatory events related to the preeclampsia market?
What is the structure of clinical trial landscape by status related to the preeclampsia market?
What is the structure of clinical trial landscape by phase related to the preeclampsia market?
What is the structure of clinical trial landscape by route of administration related to the preeclampsia market?
The preeclampsia market has been comprehensively analyzed in IMARC's new report titled "Preeclampsia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Preeclampsia is a pregnancy-related complication that typically affects after the 20th week of pregnancy and is characterized by high blood pressure and damage to organs, such as the liver and kidneys. In some cases, this condition can be life-threatening for both the mother and the baby, and it may lead to preterm delivery or other health issues. The common symptoms of the ailment include high blood pressure, proteinuria, decreased platelet levels in the blood, increased liver enzymes, severe headaches, changes in vision, shortness of breath, pain in the upper belly, nausea, vomiting, sudden appearance of edema, etc. The diagnosis of preeclampsia is based on a review of the patient's symptoms, medical history, and a physical exam. The healthcare provider may also perform other frequently used diagnostic investigations, such as fetal ultrasound, urine analysis, blood workup, non-stress test, or biophysical profile.
The rising cases of placental-related diseases on account of reduced blood supply to the placenta, resulting in a hypoxic environment, are primarily driving the preeclampsia market. In addition to this, the increasing incidences of several associated risk factors, including genetic aspects, blood vessel problems, multiple pregnancies, advancing age, autoimmune disorders, obesity, use of in vitro fertilization, etc., are also bolstering the market growth. Furthermore, the widespread adoption of intravenous antihypertensive drugs to lower blood pressure in patients with quicker onset of action than oral therapy is acting as another significant growth-inducing factor. In line with this, the escalating demand for steroid injections that help the baby's lungs mature more quickly before being born, reduce fetal abnormalities, and improve outcomes in preterm birth, is also creating a positive outlook for the market. Moreover, various stakeholders are making significant investments in research activities to develop novel diagnostic tools for early detection of the condition and encourage treatment monitoring among the population. This, in turn, is also augmenting the market growth. Additionally, the emerging popularity of angiogenic biomarkers, which accelerate diagnosis and minimize adverse maternal outcomes to help enable risk stratification, along with appropriate resource redistribution, is expected to drive the preeclampsia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the preeclampsia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for preeclampsia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the preeclampsia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the preeclampsia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the preeclampsia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current preeclampsia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Drugs Company Name
Antithrombin gamma Kyowa Kirin
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the preeclampsia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the preeclampsia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the preeclampsia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of preeclampsia across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of preeclampsia by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of preeclampsia by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with preeclampsia across the seven major markets?
What is the size of the preeclampsia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of preeclampsia?
What will be the growth rate of patients across the seven major markets?
Preeclampsia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for preeclampsia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the preeclampsia market?
What are the key regulatory events related to the preeclampsia market?
What is the structure of clinical trial landscape by status related to the preeclampsia market?
What is the structure of clinical trial landscape by phase related to the preeclampsia market?
What is the structure of clinical trial landscape by route of administration related to the preeclampsia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PREECLAMPSIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PREECLAMPSIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PREECLAMPSIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PREECLAMPSIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PREECLAMPSIA - UNMET NEEDS
10 PREECLAMPSIA - KEY ENDPOINTS OF TREATMENT
11 PREECLAMPSIA - MARKETED PRODUCTS
11.1 List of Preeclampsia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PREECLAMPSIA - PIPELINE DRUGS
12.1 List of Preeclampsia Pipeline Drugs Across the Top 7 Markets
12.1.1 Antithrombin gamma - Kyowa Kirin
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PREECLAMPSIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PREECLAMPSIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PREECLAMPSIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Preeclampsia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Preeclampsia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Preeclampsia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Preeclampsia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Preeclampsia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Preeclampsia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Preeclampsia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Preeclampsia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Preeclampsia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Preeclampsia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Preeclampsia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Preeclampsia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Preeclampsia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Preeclampsia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Preeclampsia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Preeclampsia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Preeclampsia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Preeclampsia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Preeclampsia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Preeclampsia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Preeclampsia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Preeclampsia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Preeclampsia - Access and Reimbursement Overview
16 PREECLAMPSIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PREECLAMPSIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PREECLAMPSIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PREECLAMPSIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PREECLAMPSIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PREECLAMPSIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 PREECLAMPSIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PREECLAMPSIA - UNMET NEEDS
10 PREECLAMPSIA - KEY ENDPOINTS OF TREATMENT
11 PREECLAMPSIA - MARKETED PRODUCTS
11.1 List of Preeclampsia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PREECLAMPSIA - PIPELINE DRUGS
12.1 List of Preeclampsia Pipeline Drugs Across the Top 7 Markets
12.1.1 Antithrombin gamma - Kyowa Kirin
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. PREECLAMPSIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PREECLAMPSIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PREECLAMPSIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Preeclampsia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Preeclampsia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Preeclampsia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Preeclampsia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Preeclampsia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Preeclampsia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Preeclampsia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Preeclampsia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Preeclampsia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Preeclampsia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Preeclampsia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Preeclampsia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Preeclampsia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Preeclampsia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Preeclampsia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Preeclampsia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Preeclampsia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Preeclampsia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Preeclampsia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Preeclampsia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Preeclampsia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Preeclampsia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Preeclampsia - Access and Reimbursement Overview
16 PREECLAMPSIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PREECLAMPSIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PREECLAMPSIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
